Is Axsome Therapeutics (AXSM) Undervalued As Caregiver Survey Data Tests Its CNS Growth Story?
Axsome Therapeutics (AXSM) put caregiver experience in the spotlight with new Shared Goals survey data on Alzheimer’s agitation, presented at Psych Congress 2026 and sponsored by the company.
Axsome Therapeutics has seen its recent momentum cool, with the share price down 6.1% over the past week and 19.1% over the past three months. However, the 12 month total shareholder return of 67.1% and 3 year total shareholder return near 3x still point to a strong longer term run as investors weigh product updates like the Shared Goals data against changing expectations on risk and future execution.
Scan how Axsome Therapeutics compares with other potential breakouts in CNS and healthcare by reviewing our curated list of 38 healthcare AI stocks.
Axsome Therapeutics trades at about $195, while the average analyst target and intrinsic value estimates sit much higher. Is the recent pullback closing that gap, or is it opening up a wider valuation debate?
Most Popular Narrative: 31% Undervalued
On the narrative numbers, Axsome Therapeutics screens as undervalued, with a fair value estimate of about $282.51 against the recent $195.09 close. This puts execution on its late stage CNS pipeline squarely in focus for investors.
The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications). This positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.
See why 40 investors see Axsome Therapeutics as 31% undervalued.
The most followed narrative applies a 7.11% discount rate and arrives at a fair value of $282.51 per share, around 31% above where Axsome Therapeutics currently trades. That gap reflects expectations for revenue to reach $2.5b and earnings of $908.3m by 2029, paired with a future P/E of 21.4x that sits above the 15.1x level used for the wider US Pharmaceuticals group in the same framework.
Analysts within this narrative also flag that Axsome Therapeutics is trading at 78.5% below an estimated future cash flow value of $906.21, and that earnings are forecast to grow 61.29% per year as margins move from current losses toward a modeled 37.1%. Those inputs help explain why the story casts the shares as undervalued, even though the business is still reporting losses and relies on external borrowing as a higher risk funding source.
On balance, the widely tracked view is that Axsome Therapeutics offers upside if the CNS portfolio and upcoming regulatory decisions track these projections. The same narrative also highlights real risks around payer pressure, competition and liquidity that could challenge those assumptions.
Result: Fair Value of $282.51 (UNDERVALUED)
Still, the Axsome Therapeutics narrative can crack if payer pushback keeps net pricing under strain, or if heavy SG&A spending extends the path to profitability.
Find out about the key risks to this Axsome Therapeutics narrative.
Next Steps
Positive sentiment around Axsome Therapeutics is clear, so it makes sense to move quickly and test the assumptions against your own research before the narrative shifts. To see what optimism is grounded in the underlying data, take a closer look at the 3 key rewards.
Looking for more Axsome Therapeutics investment ideas?
If Axsome Therapeutics has your attention, do not stop here. Broaden your watchlist with fresh setups that match your risk, income, and quality preferences.
- Target potential value opportunities early by scanning the 32 high quality undervalued stocks that score well on both quality and price.
- Lock in income-focused ideas by reviewing the 8 dividend fortresses that pair higher yields with resilient payout profiles.
- Prioritise financial strength by filtering for a list of solid balance sheet and fundamentals (24 results) that can better withstand funding stress and operational surprises.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com